Truncating variants in CHEK2 were associated with a higher relative risk for ER-positive (OR=3.42; 95% CI 2.33 to 5.21; table 2), and lower, non-significant risk for ER-negative BC (OR=1.59; 95% CI 0.80 to 3.00; Pdiff=0.0032). This evidence concerns the gene CHEK2 and breast cancer.